The clinical effect of the inhibitor of apopotosis protein livin in melanoma

Oncology

Volumn 82, Issue 4, 2012, Pages 197-204

  Lazar, Itay ^a   Perlman, Riki ^a   Lotem, Michal ^a   Peretz, Tamar ^a   Ben Yehuda, Dina ^a   Kadouri, Luna ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Inhibitor of apoptosis protein; Livin; Melanoma; Survival

Indexed keywords

B RAF KINASE; BETA ACTIN; CASPASE; K RAS PROTEIN; LIVIN; MELANOMA VACCINE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MYC PROTEIN; PROTEIN BCL 2; TUBULIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PREVENTION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; APOPTOSIS; CANCER VACCINES; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84858741627     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000334234     Document Type: Article

References (29)

1. Nachmias B, Ashhab Y, Ben-Yehuda D: The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 2004; 14: 231-243. (Pubitemid 38824584)
2. Kasof GM, Gomes BC: Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001; 276: 3238-3246.
3. Lin JH, Deng G, Huang Q, Morser J: KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem Biophys Res Commun 2000; 279: 820-831. (Pubitemid 32042862)
4. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000; 10: 1359-1366.
5. Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, Peretz T, Mandelboim O, Ben-Yehuda D: Caspase-mediated cleavage converts livin from an antiapoptotic to a proapoptotic factor: implications for drugresistant melanoma. Cancer Res 2003; 63: 6340-6349. (Pubitemid 37255182)
6. Nachmias B, Lazar I, Elmalech M, Abed-El-Rahaman I, Asshab Y, Mandelboim O, Perlman R, Ben-Yehuda D: Subcellular localization determines the delicate balance between the anti-and pro-apoptotic activity of livin. Apoptosis 2007; 12: 1129-1142. (Pubitemid 46890380)
7. Kim DK, Alvarado CS, Abramowsky CR, Gu L, Zhou M, Soe MM, Sullivan K, George B, Schemankewitz E, Findley HW: Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. Pediatr Dev Pathol 2005; 8: 621-629. (Pubitemid 41830922)
8. Gazzaniga P, Gradilone A, Giuliani L, Gandini O, Silvestri I, Nofroni I, Saccani G, Frati L, Agliano AM: Expression and prognostic significance of livin, survivin and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003; 14: 85-90. (Pubitemid 36150264)
9. Choi J, Hwang YK, Sung KW, Lee SH, Yoo KH, Jung HL, Koo HH, Kim HJ, Kang HJ, Shin HY, Ahn HS: Expression of livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 2007; 109: 471-477. (Pubitemid 46105940)
10. Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Edenfield HR, Glickman JN, Yeap BY, Sugarbaker DJ, Bueno R: Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 2007; 211: 447-454. (Pubitemid 46332556)
11. Xiang Y, Yao H, Wang S, Hong M, He J, Cao S, Min H, Song E, Guo X: Prognostic value of survivin and livin in nasopharyngeal carcinoma. Laryngoscope 2006; 116: 126-130. (Pubitemid 44383976)
12. Tanabe H, Yagihashi A, Tsuji N, Shijubo Y, Abe S, Watanabe N: Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung Cancer 2004; 46: 299-304. (Pubitemid 39487304)
13. Yagihashi A, Asanuma K, Kobayashi D, Tsuji N, Shijubo Y, Abe S, Hirohashi Y, Torigoe T, Sato N, Watanabe N: Detection of autoantibodies to livin and survivin in sera from lung cancer patients. Lung Cancer 2005; 48: 217-221.
14. Chang H, Schimmer AD: Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy. Mol Cancer Ther 2007; 6: 24-30. (Pubitemid 46206665)
15. Takeuchi H, Morton DL, Elashoff D, Hoon DS: Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer 2005; 117: 1032-1038. (Pubitemid 41688581)
16. Liu T, Brouha B, Grossman D: Rapid induction of mitochondrial events and caspaseindependent apoptosis in survivin-targeted melanoma cells. Oncogene 2004; 23: 39-48. (Pubitemid 38142238)
17. Gong J, Chen N, Zhou Q, Yang B, Wang Y, Wang X: Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas. J Clin Pathol 2005; 58: 1081-1085. (Pubitemid 41416059)
18. Bowen AR, Hanks AN, Allen SM, Alexander A, Diedrich MJ, Grossman D: Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol 2003; 120: 48-55. (Pubitemid 36120970)
19. Yan H, Brouha B, Liu T, Raj D, Biddle D, Lee R, Grossman D: Proteolytic cleavage of livin (ML-IAP) in apoptotic melanoma cells potentially mediated by a non-canonical caspase. J Dermatol Sci 2006; 43: 189-200. (Pubitemid 44189199)
20. Dynek JN, Chan SM, Liu J, Zha J, Fairbrother WJ, Vucic D: Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res 2008; 68: 3124-3132.
21. Lotem M, Peretz T, Drize O, Gimmon Z, Ad El D, Weitzen R, Goldberg H, Ben David I, Prus D, Hamburger T, Shiloni E: Autologous cell vaccine as a postoperative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The New American Joint Committee on Cancer. Br J Cancer 2002; 86: 1534-1539. (Pubitemid 34628104)
22. Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, Isacson R, Kaduri L, Merims S, Frankenburg S, Peretz T: Interleukin-2 improves tumour response to DNPmodified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer 2004; 90: 773-780. (Pubitemid 38406585)
23. Libra M, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L, Bruni B, Stivala F, Mazzarino MC, Travali S, Mc-Cubrey JA: Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 2005; 4: 1382-1384. (Pubitemid 41437127)
24. Shinozaki M, Fujimoto A, Morton DL, Hoon DS: Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004; 10: 1753-1757. (Pubitemid 38435567)
25. Abd-Elrahman I, Hershko K, Neuman T, Nachmias B, Perlman R, Ben-Yehuda D: The inhibitor of apoptosis protein livin (MLIAP) plays a dual role in tumorigenicity. Cancer Res 2009; 69: 5475-5480.
26. Andersen MH, Reker S, Becker JC, thor Straten P: The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. J Invest Dermatol 2004; 122: 392-399. (Pubitemid 38281060)
27. Zhang Y, Luoh SM, Hon LS, Baertsch R, Wood WI, Zhang Z: GeneHub-GEPIS: digital expression profiling for normal and cancer tissues based on an integrated gene database. Nucleic Acids Res 2007; 35:W152-W158.
28. Barks JH, Thompson FH, Taetle R, Yang JM, Stone JF, Wymer JA, Khavari R, Guan XY, Trent JM, Pinkel D, Nelson MA: Increased chromosome 20 copy number detected by fluorescence in situ hybridization (FISH) in malignant melanoma. Genes Chromosomes Cancer 1997; 19: 278-285. (Pubitemid 27330240)
29. Koynova D, Jordanova E, Kukutsch N, van der Velden P, Toncheva D, Gruis N: Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma. J Cancer Res Clin Oncol 2007; 133: 117-123. (Pubitemid 44950244)